Patents Assigned to Celularity, Inc.
-
Publication number: 20220096352Abstract: The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.Type: ApplicationFiled: May 13, 2021Publication date: March 31, 2022Applicant: Celularity Inc.Inventors: Mohit B. BHATIA, Chris LUGO, Qian YE, James W. EDINGER
-
Publication number: 20220072063Abstract: Provided herein are methods of using CD10+, CD34?, CD105+, CD200+ tissue culture plastic-adherent placental cells, e.g. placental stem cells, in the treatment of diabetic peripheral neuropathy (DPN).Type: ApplicationFiled: November 17, 2021Publication date: March 10, 2022Applicant: Celularity Inc.Inventors: Steven FISCHKOFF, Denesh CHITAKARA, Robert J. HARIRI
-
Publication number: 20220000919Abstract: Provided herein are methods of using populations of natural killer (NK) cells and/or ILC3 cells derived from a population of hematopoietic stem or progenitor cells in methods for treating a viral infection, e.g., a coronavirus infection.Type: ApplicationFiled: January 29, 2021Publication date: January 6, 2022Applicant: Celularity Inc.Inventors: Lin KANG, William VAN DER TOUW, Vanesssa VOSKINARIAN-BERSE, Xuan GUO, Robert J. HARIRI, Xiaokui ZHANG, Catherine BALINT, Nassir HABBOUBI, Stacy HERB, Sharmila KOPPISETTI, Tanel MAHLAKOIV, Bhavani STOUT, Junhong ZHU, Corey CASPER, Shuyang HE
-
Patent number: 11180731Abstract: Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three-stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells.Type: GrantFiled: May 5, 2017Date of Patent: November 23, 2021Assignee: Celularity Inc.Inventors: Steven A. Fischkoff, Uri Herzberg, Lin Kang, Brian Murphy, Andrea Nordberg, Vanessa Voskinarian-Berse, Keith Wilson, Xiaokui Zhang, Han Myint, Mohamad Hussein, Robert J Hariri
-
Patent number: 11173182Abstract: Provided herein are compositions of placenta-derived adherent cell exosomes and methods of making and using the same. In one aspect, provided herein are compositions comprising exosomes produced by and/or derived from placental cells, e.g., placenta-derived adherent cells. In certain embodiments, the exosomes provided herein are produced by placenta-derived adherent cells that have been cultured in vitro for, e.g., 1, 2, 3, 4, 5, 6 or more passages.Type: GrantFiled: January 10, 2020Date of Patent: November 16, 2021Assignee: Celularity Inc.Inventors: Eric Law, Andrew Morschauser, Aleksander Francki, Jennifer Paredes, Kathy Karasiewicz-Mendez, Allan Reduta, Vladimir Jankovic, Ivana Djuretic, Robert J. Hariri
-
Publication number: 20210289769Abstract: Provided herein are improved methods for the formulation of compositions comprising placental stem cells, and improved compositions and cell formulations produced thereby.Type: ApplicationFiled: June 7, 2021Publication date: September 23, 2021Applicant: Celularity Inc.Inventors: Andy ZEITLIN, Gregory RUSSOTTI, Shuyang HE, Ajai PAL, Hong CHEN, Thomas BRIEVA, Ryan SHORR, Brian MURPHY
-
Publication number: 20210253327Abstract: Provided herein are devices and methods for thawing frozen biological material.Type: ApplicationFiled: April 30, 2021Publication date: August 19, 2021Applicant: Celularity Inc.Inventors: Brian Murphy, Robert J. Hariri
-
Patent number: 11090339Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).Type: GrantFiled: August 5, 2019Date of Patent: August 17, 2021Assignee: Celularity Inc.Inventors: Uri Herzberg, Jodi P. Gurney, Robert J. Hariri
-
Publication number: 20210238544Abstract: Provided herein are placental stem cells that exhibit increased survival (“enhanced placental stem cells”), compositions comprising such placental stem cells, and methods of using such placental stem cells and compositions.Type: ApplicationFiled: April 15, 2019Publication date: August 5, 2021Applicant: CELULARITY, INC.Inventors: Stewart Abbot, Kathy Karasiewicz-Mendez, Xiaokui Zhang
-
Publication number: 20210230546Abstract: Provided herein are methods for the isolation of platelets, for example, isolation of platelets from umbilical cord blood. In certain embodiments, presented herein are methods for preparation of platelet rich plasma. In one aspect, provided herein are methods for isolation of platelets from blood. In certain embodiments, presented herein are methods for isolation of platelets from cord blood, e.g., human cord blood. The isolated platelets can be used for a variety of applications, including, for example, methods of wound healing, organ repair and/or regeneration, and/or tissue repair and/or regeneration, in either autologous or allogeneic settings.Type: ApplicationFiled: April 6, 2021Publication date: July 29, 2021Applicant: Celularity Inc.Inventors: Manoochehr KHORSHIDI, Robert J. HARIRI, Xiaokui ZHANG
-
Publication number: 20210230537Abstract: Provided herein are stimulated placental stem cells and methods of treating individuals having diseases or disorders of the circulatory system using stimulated placental cells. The invention also provides methods of inducing angiogenesis using such stimulated cells or populations of cells comprising such stimulated cells.Type: ApplicationFiled: January 7, 2021Publication date: July 29, 2021Applicant: Celularity Inc.Inventors: Kathy E. KARASIEWICZ-MENDEZ, Aleksander FRANCKI, Jeffrey TURNER, Eric LAW, Jennifer PAREDES, Kristen LABAZZO, Hemlata RANA, Wolfgang HOFGARTNER, Robert J. HARIRI
-
Publication number: 20210145872Abstract: Provided herein are methods for forming three-dimensional tissues in vivo. In one embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells. In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells and at least one composition that comprises an extracellular matrix (ECM). In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells, at least one composition that comprises an extracellular matrix (ECM), and at least one other additional components.Type: ApplicationFiled: June 23, 2020Publication date: May 20, 2021Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Mohit B. BHATIA, Wolfgang HOFGARTNER, Jia-Lun WANG, Qian YE
-
Publication number: 20210121452Abstract: Provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising contacting the tumor cells, or administering to the individual, placental perfusate, placental perfusate cells, or natural killer cells, e.g., placenta-derived intermediate natural killer cells, with an immunomodulatory compound or thalidomide.Type: ApplicationFiled: June 2, 2020Publication date: April 29, 2021Applicant: Celularity Inc.Inventors: Xiaokui ZHANG, LIn KANG, Mohammad A. HEIDARAN, Stephen JASKO, Andrew ZEITLIN, Ajai PAL, Robert J. HARIRI
-
Publication number: 20210095258Abstract: The present invention provides an induced pluripotent stem (iPS) cell, or population of iPS cells, wherein the cell or cells giving rise to the iPS cell(s) are obtained from human postpartum tissue or cells, wherein the iPS cell(s) have increased levels of one or more factors selected from Group I: an Oct family member, a Sox family member, a Klf family member, a Myc family member, Nanog, Lin28, and combinations thereof. The present invention also provides differentiated cells derived from the cells of the invention and compositions, including pharmaceutical compositions comprising the cells of the invention. The invention further provides uses of the cells of the invention, e.g., in the treatment of a subject suffering from a disease of disorder. The invention additionally provides methods of generating iPS cell(s) from postpartum tissue, such as the cells of the invention.Type: ApplicationFiled: February 22, 2019Publication date: April 1, 2021Applicant: Celularity Inc.Inventors: James EDINGER, Robert J. HARIRI, Sourav SINHA, Xiaokui ZHANG
-
Publication number: 20210032596Abstract: Provided herein are methods of producing erythrocytes from hematopoietic cells, particularly hematopoietic cells from placental perfusate in combination with hematopoietic cells from umbilical cord blood, wherein the method results in accelerated expansion and differentiation of the hematopoietic cells to more efficiently produce administrable erythrocytes. Further provided herein is a bioreactor in which hematopoietic cell expansion and differentiation takes place.Type: ApplicationFiled: March 12, 2020Publication date: February 4, 2021Applicant: Celularity, Inc.Inventors: Mohammad A. Heidaran, Xiaokui Zhang, Lin Kang, Andrew Zeitlin, Vanessa Voskinarian-Berse, Stewart Abbot
-
Publication number: 20210002606Abstract: Provided herein are methods of culturing cells using microcarriers that include extracellular matrix (ECM).Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Mohit BHATIA
-
Publication number: 20200397830Abstract: Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.Type: ApplicationFiled: January 24, 2020Publication date: December 24, 2020Applicant: CELULARITY, INC.Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Herbert Faleck
-
Publication number: 20200330516Abstract: Provided herein are methods of producing natural killer (NK) cells using a three-stage expansion and differentiation method with media comprising stem cell mobilizing factors. Also provided herein are methods of suppressing tumor cell proliferation using the NK cells and the NK cell populations produced by the three-stage methods described herein, as well as methods of treating individuals having cancer or a viral infection, comprising administering the NK cells and the NK cell populations produced by the three-stage methods described herein to an individual having the cancer or viral infection.Type: ApplicationFiled: May 18, 2020Publication date: October 22, 2020Applicant: Celularity Inc.Inventors: Brian MURPHY, Vanessa VOSKINARIAN-BERSE, Andrea NORDBERG, Keith WILSON, Lin KANG
-
Publication number: 20200246393Abstract: Provided herein are methods of suppressing the growth or proliferation of tumor cells and methods of treating individuals having tumor cells using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer (PINK) cells, combined natural killer (NK) cells, or combinations thereof, in combination with an antibody (e.g., anti-disialoganglioside (anti-GD2) antibody). Also provided herein are compositions comprising placental perfusate, placental perfusate cells, PINK cells, combined NK cells, or combinations thereof, in combination with an antibody (e.g., anti-GD2 antibody).Type: ApplicationFiled: September 27, 2018Publication date: August 6, 2020Applicant: CELULARITY, INC.Inventors: Xiaokui ZHANG, Lin KANG, Robert J. HARIRI
-
Publication number: 20200246385Abstract: Provided herein are micro-organoids, referred to herein as Functional Physiological Units (FPUs), that are capable of replacing or augmenting one or more physiological functions in an individual, which are useful in the treatment of individuals lacking, or suffering a deficit in, said physiological function.Type: ApplicationFiled: April 21, 2020Publication date: August 6, 2020Applicant: Celularity Inc.Inventors: Robert J. HARIRI, Mohit BHATIA, Jia-Lun WANG, Wolfgang HOFGARTNER, Qian YE